Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Repligen Q3 revenue beats estimates on higher demand; lifts outlook

By Reuters News


Overview

  • US bioprocessing tech firm's Q3 revenue rose 11%, beating analyst expectations

  • Q3 adjusted EPS beat analyst expectations

  • Company closed BioLife acquisition and raised FY26 revenue guidance


Outlook

  • Repligen raises FY26 revenue guidance to $844 mln-$852 mln, up 14.5%-15.5%

  • Company expects FY26 organic revenue growth of 12%-13%

  • Repligen forecasts FY26 adjusted EPS of $2.05-$2.09


Result Drivers

  • PORTFOLIO STRENGTH - Co said revenue growth was driven by continued strength across its diversified portfolio

  • IMPROVING DEMAND - Co said end-market demand continues to improve, with healthy trends in consumables and services and a growing capital equipment order book

  • BIOLIFE ACQUISITION - Co said completion of BioLife acquisition strengthens position in cell therapy market and expands portfolio


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$209 mln

$206.62 mln (18 Analysts)

Q3 Adjusted EPS

Beat

$0.53

$0.46 (17 Analysts)

Q3 Adjusted Operating Income

$33.30 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Repligen Corporation is $200.00, about 11% above its October 26 closing price of $180.17

  • The stock recently traded at 71 times the next 12-month earnings vs. a P/E of 60 three months ago


Reuters Recommended Reads

  • Oct 27 - Nautilus Biotechnology Q3 revenue beats

  • Oct 26 - China's WuXi AppTec nine-month revenue rises on chemistry segment growth; lifts 2026 outlook

  • Oct 27 - Novartis slightly misses Q3 net sales estimates, but tops core EPS view


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.